193 related articles for article (PubMed ID: 20942909)
21. HSV/AAV hybrid amplicon vectors extend transgene expression in human glioma cells.
Johnston KM; Jacoby D; Pechan PA; Fraefel C; Borghesani P; Schuback D; Dunn RJ; Smith FI; Breakefield XO
Hum Gene Ther; 1997 Feb; 8(3):359-70. PubMed ID: 9048203
[TBL] [Abstract][Full Text] [Related]
22. Apoptosis by retrovirus- and adenovirus-mediated gene transfer of Fas ligand to glioma cells: implications for gene therapy.
Shinoura N; Yoshida Y; Sadata A; Hanada KI; Yamamoto S; Kirino T; Asai A; Hamada H
Hum Gene Ther; 1998 Sep; 9(14):1983-93. PubMed ID: 9759926
[TBL] [Abstract][Full Text] [Related]
23. Multitracer positron emission tomographic imaging of exogenous gene expression mediated by a universal herpes simplex virus 1 amplicon vector.
Kummer C; Winkeler A; Dittmar C; Bauer B; Rueger MA; Rueckriem B; Heneka MT; Vollmar S; Wienhard K; Fraefel C; Heiss WD; Jacobs AH
Mol Imaging; 2007; 6(3):181-92. PubMed ID: 17532884
[TBL] [Abstract][Full Text] [Related]
24. Imaging herpes simplex virus type 1 amplicon vector-mediated gene expression in human glioma spheroids.
Kaestle C; Winkeler A; Richter R; Sauer H; Hescheler J; Fraefel C; Wartenberg M; Jacobs AH
Mol Imaging; 2011 Jun; 10(3):197-205. PubMed ID: 21443839
[TBL] [Abstract][Full Text] [Related]
25. Evaluation of genetically engineered herpes simplex viruses as oncolytic agents for human malignant brain tumors.
Andreansky S; Soroceanu L; Flotte ER; Chou J; Markert JM; Gillespie GY; Roizman B; Whitley RJ
Cancer Res; 1997 Apr; 57(8):1502-9. PubMed ID: 9108452
[TBL] [Abstract][Full Text] [Related]
26. Use of viral fusogenic membrane glycoproteins as novel therapeutic transgenes in gliomas.
Galanis E; Bateman A; Johnson K; Diaz RM; James CD; Vile R; Russell SJ
Hum Gene Ther; 2001 May; 12(7):811-21. PubMed ID: 11339897
[TBL] [Abstract][Full Text] [Related]
27. Ex vivo malignant glioma cells are sensitive to Fas (CD95/APO-1) ligand-mediated apoptosis.
Frei K; Ambar B; Adachi N; Yonekawa Y; Fontana A
J Neuroimmunol; 1998 Jul; 87(1-2):105-13. PubMed ID: 9670851
[TBL] [Abstract][Full Text] [Related]
28. Overexpression of CDC2/CyclinB1 in gliomas, and CDC2 depletion inhibits proliferation of human glioma cells in vitro and in vivo.
Chen H; Huang Q; Dong J; Zhai DZ; Wang AD; Lan Q
BMC Cancer; 2008 Jan; 8():29. PubMed ID: 18230152
[TBL] [Abstract][Full Text] [Related]
29. Gene transfer into hepatocytes mediated by helper virus-free HSV/AAV hybrid vectors.
Fraefel C; Jacoby DR; Lage C; Hilderbrand H; Chou JY; Alt FW; Breakefield XO; Majzoub JA
Mol Med; 1997 Dec; 3(12):813-25. PubMed ID: 9440115
[TBL] [Abstract][Full Text] [Related]
30. RNA interference targeting survivin exerts antitumoral effects in vitro and in established glioma xenografts in vivo.
Hendruschk S; Wiedemuth R; Aigner A; Töpfer K; Cartellieri M; Martin D; Kirsch M; Ikonomidou C; Schackert G; Temme A
Neuro Oncol; 2011 Oct; 13(10):1074-89. PubMed ID: 21788344
[TBL] [Abstract][Full Text] [Related]
31. Adenovirus-mediated expression of HSV1-TK or Fas ligand induces cell death in primary human glioma-derived cell cultures that are resistant to the chemotherapeutic agent CCNU.
Maleniak TC; Darling JL; Lowenstein PR; Castro MG
Cancer Gene Ther; 2001 Aug; 8(8):589-98. PubMed ID: 11571537
[TBL] [Abstract][Full Text] [Related]
32. Induction of apoptosis in glioma cells by recombinant human Fas ligand.
Kawaguchi S; Mineta T; Ichinose M; Masuoka J; Shiraishi T; Tabuchi K
Neurosurgery; 2000 Feb; 46(2):431-8; discussion 438-9. PubMed ID: 10690733
[TBL] [Abstract][Full Text] [Related]
33. Topotecan enhances immune clearance of gliomas.
Wei J; DeAngulo G; Sun W; Hussain SF; Vasquez H; Jordan J; Weinberg J; Wolff J; Koshkina N; Heimberger AB
Cancer Immunol Immunother; 2009 Feb; 58(2):259-70. PubMed ID: 18594817
[TBL] [Abstract][Full Text] [Related]
34. Single-step conversion of cells to retrovirus vector producers with herpes simplex virus-Epstein-Barr virus hybrid amplicons.
Sena-Esteves M; Saeki Y; Camp SM; Chiocca EA; Breakefield XO
J Virol; 1999 Dec; 73(12):10426-39. PubMed ID: 10559361
[TBL] [Abstract][Full Text] [Related]
35. Treatment of malignant gliomas with a replicating adenoviral vector expressing herpes simplex virus-thymidine kinase.
Nanda D; Vogels R; Havenga M; Avezaat CJ; Bout A; Smitt PS
Cancer Res; 2001 Dec; 61(24):8743-50. PubMed ID: 11751394
[TBL] [Abstract][Full Text] [Related]
36. A non-viral suicide gene delivery system traversing the blood brain barrier for non-invasive glioma targeting treatment.
Gao S; Tian H; Xing Z; Zhang D; Guo Y; Guo Z; Zhu X; Chen X
J Control Release; 2016 Dec; 243():357-369. PubMed ID: 27794494
[TBL] [Abstract][Full Text] [Related]
37. The potential application of a transcriptionally regulated oncolytic herpes simplex virus for human cancer therapy.
Miao L; Fraefel C; Sia KC; Newman JP; Mohamed-Bashir SA; Ng WH; Lam PY
Br J Cancer; 2014 Jan; 110(1):94-106. PubMed ID: 24196790
[TBL] [Abstract][Full Text] [Related]
38. Treatment of experimental glioma by administration of adenoviral vectors expressing Fas ligand.
Ambar BB; Frei K; Malipiero U; Morelli AE; Castro MG; Lowenstein PR; Fontana A
Hum Gene Ther; 1999 Jul; 10(10):1641-8. PubMed ID: 10428209
[TBL] [Abstract][Full Text] [Related]
39. A novel bystander effect involving tumor cell-derived Fas and FasL interactions following Ad.HSV-tk and Ad.mIL-12 gene therapies in experimental prostate cancer.
Hall SJ; Canfield SE; Yan Y; Hassen W; Selleck WA; Chen SH
Gene Ther; 2002 Apr; 9(8):511-7. PubMed ID: 11948376
[TBL] [Abstract][Full Text] [Related]
40. Herpes simplex virus type-1 amplicon vectors for vaccine generation in acute lymphoblastic leukemia.
Zibert A; Thomassen A; Müller L; Nguyen L; Glouchkova L; Fraefel C; Roskrow M; Meisel R; Dilloo D
Gene Ther; 2005 Dec; 12(23):1707-17. PubMed ID: 16034459
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
